List view / Grid view
An executive from Sanofi has been appointed as Johnson &…
An executive from Sanofi has been appointed as Johnson & Johnson’s new Executive Vice President of Pharmaceuticals, R&D.
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying…
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
The investment will advance the development of a subcutaneous Sarclisa…
The investment will advance the development of a subcutaneous Sarclisa (isatuximab) formulation for multiple myeloma (MM) treatment.
Sanofi invests $180 million equity in Owkin’s artificial intelligence (AI)…
Sanofi invests $180 million equity in Owkin’s artificial intelligence (AI) and federated learning to advance oncology pipeline.
Dupixent® is the first biologic to significantly reduce itch and…
Dupixent® is the first biologic to significantly reduce itch and skin lesions in Phase III trial for prurigo nodularis.
The EC has approved an extension of marketing authorisation for…
The EC has approved an extension of marketing authorisation for Regeneron and Sanofi's Dupixent (dupilumab) for children aged six to 11 with severe atopic dermatitis.
In combination with inhaled corticosteroids, the monoclonal antibody Dupixent improved…
In combination with inhaled corticosteroids, the monoclonal antibody Dupixent improved lung function and reduced the rate of severe asthma attacks.
After Kevzara (sarilumab) did not meet its primary or secondary…
After Kevzara (sarilumab) did not meet its primary or secondary endpoints in a Phase III trial, Sanofi and Regeneron have said they do not expect to conduct further studies on the drug against COVID-19.
The FDA has granted priority review of the Biologics License…
The FDA has granted priority review of the Biologics License Application for sutimlimab to treat haemolysis in patients with cold agglutinin disease (CAD).
Led by Sanofi and Regeneron, clinical trials to examine Kevzara…
Led by Sanofi and Regeneron, clinical trials to examine Kevzara (sarilumab) as an effective COVID-19 treatment will begin in the US.
According to its developers, SAR442168 significantly reduced the appearance of…
According to its developers, SAR442168 significantly reduced the appearance of new gadolinium (Gd)-enhancing T1-hyperintense brain lesions in the 120 trial patients.
